anastasios gianakakos   zoominfocom insider trading  gianakakos anastasios  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  gianakakos anastasios select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm myokardia inc myok gianakakos anastasiospresident and ceodirector    indirectdirect view purchase  pm myokardia inc myok gianakakos anastasiospresident and ceodirector    indirectdirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm nana myokardia inc myok gianakakos anastasiospresident and ceodirector   direct view option award  pm  myokardia inc myok gianakakos anastasiospresident and ceodirector   direct view option award  pm na myokardia inc myok gianakakos anastasiospresident and ceodirector   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version tassos anastasios gianakakos executive profile  biography  bloomberg july    pm et pharmaceuticals company overview of myokardia inc snapshotpeople  overviewboard memberscommittees executive profile tassos anastasios gianakakos chief executive officer president and director myokardia incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background mr tassos anastasios gianakakos has been the president and chief executive officer at myokardia inc since october  mr gianakakos has more than  years of broadbased biopharmaceutical expertise to myokardia he joined myokardia from map pharmaceuticals acquired by allergan in march  where he served as senior vice president and chief business officer prior to map he led the formation of codexis inc where he served as president and senior vice president  of business development and global head of codexis pharmaceuticals business unit before forming codexis he served as director of business development at maxygen where he led its business development efforts for its vaccine and bioindustrial platforms prior to maxygen he was a process engineer in merck  cos vaccine division he has been a director at myokardia inc since october  mr gianakakos holds bsc degrees in chemical engineering and economics from the massachusetts institute of technology an msc in biotechnology from northwestern university and an mba from harvard business schoolread full background corporate headquarters  allerton avenuesouth san francisco california united statesphone fax  board members memberships presentchief executive officer president and directormyokardia inc education mba harvard business schoolbs massachusetts institute of technologyms northwestern university other affiliations harvard business schoolmassachusetts institute of technologynorthwestern university annual compensation salarytotal annual compensation stocks options all other compensationexercisable optionsunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact myokardia inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft myokardia nasdaqmyok stock price news  analysis  marketbeat myokardia company profile nasdaqmyok company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about myokardia nasdaqmyok myokardia inc is a clinicalstage biopharmaceutical company the company focuses on the treatment of heritable cardiomyopathies a group of rare geneticallydriven forms of heart failure that result from biomechanical defects in cardiac muscle contraction the company is engaged in the business of developing and commercializing therapeutics the company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathyhypertrophic cardiomyopathy hcm and dilated cardiomyopathy dcm additionally the company has three preclinical programs hcm dcm and lus its lead product candidate myk is an orallyadministered small molecule designed to reduce excessive cardiac muscle contractility leading to hcm industry sector and symbol sector medical industry bio therapeutic drugs subindustry na symbol nasdaqmyok cusip na web wwwmyokardiacom capitalizationmarket cap  millionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue  millionprice  sales book value  per shareprice  book  profitabilityebidta net margins return on equity return on assets debtcurrent ratio quick ratio miscaverage volume  shsbeta short ratio    frequently asked questions for myokardia nasdaqmyok what is myokardias stock symbol myokardia trades on the nasdaq under the ticker symbol myok how were myokardias earnings last quarter myokardia inc nasdaqmyok announced its quarterly earnings results on tuesday may th the company reported  earnings per share for the quarter missing the consensus estimate of  by  the company had revenue of  million for the quarter compared to analyst estimates of  million myokardia had a negative return on equity of  and a negative net margin of  the firms quarterly revenue was up  on a yearoveryear basis view myokardias earnings history where is myokardias stock going where will myokardias stock price be in   brokerages have issued twelvemonth price targets for myokardias stock their predictions range from  to  on average they expect myokardias stock price to reach  in the next twelve months view analyst ratings for myokardia who are some of myokardias key competitors some companies that are related to myokardia include omeros corporation omer aduro biotech adro synergy pharmaceuticals sgyp insys therapeutics insy five prime therapeutics fprx retrophin rtrx keryx biopharmaceuticals kerx aclaris therapeutics acrs flexion therapeutics flxn ziopharm oncology ziop revance therapeutics rvnc epizyme epzm ptc therapeutics ptct achaogen akao vanda pharmaceuticals vnda coherus biosciences chrs reata pharmaceuticals reta and la jolla pharmaceutical company ljpc who are myokardias key executives myokardias management team includes the folowing people tassos anastasios gianakakos president chief executive officer directorjune lee md chief operating officerjake bauer senior vice president  finance and corporate developmentjoseph lambing phd senior vice president  nonclinical and pharmaceutical developmentrobert scott mcdowell phd senior vice president  drug discoverymarc semigran md chief medical officermark l perry jd interim nonexecutive chairman of the board lead independent directorkevin p starr directorsunil agarwal md independent directormary b cranston independent director who owns myokardia stock myokardias stock is owned by a variety of of institutional and retail investors top institutional shareholders include spark investment management llc  and hershey trust co  company insiders that own myokardia stock include anastasios gianakakos jake bauer jonathan c fox mark l perry and sanofi view institutional ownership trends for myokardia who bought myokardia stock who is buying myokardia stock myokardias stock was acquired by a variety of institutional investors in the last quarter including spark investment management llc company insiders that have bought myokardia stock in the last two years include anastasios gianakakos jonathan c fox mark l perry and sanofi view insider buying and selling for myokardia how do i buy myokardia stock shares of myokardia can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is myokardias stock price today one share of myokardia stock can currently be purchased for approximately  marketbeat community rating for myokardia nasdaq myokcommunity ranking   out of   outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about myokardia and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for myokardia nasdaqmyok how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  buy ratingsconsensus ratingbuy score consensus price target   upside analysts ratings history for myokardia nasdaqmyok show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailsbmo capital marketsreiterated ratingoutperformlowwedbushreiterated ratingoutperformhighcowen and companyreiterated ratingbuynawells fargo  companyreiterated ratingbuynacredit suisse groupreiterated ratingbuy  nadata available from  forward earnings earnings history for myokardia nasdaqmyokearnings history by quarter for myokardia nasdaq myokdatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsq  million millionviewlistenq  million millionviewnaq million millionviewnaq million millionviewnaq million millionviewnaq million millionviewnadata available from  forward estimates earnings estimates for myokardia nasdaqmyok eps consensus estimate  eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q q q q q data provided by zacks investment research dividends dividend history for myokardia nasdaqmyokno dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for myokardia nasdaqmyokinsider ownership percentage institutional ownership percentage insider trades by quarter for myokardia nasdaqmyoktransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailsanastasios gianakakosinsidersell  anastasios gianakakosceosell  jake bauerinsidersell  sanofimajor shareholderbuy  anastasios gianakakosceobuy  jonathan c foxinsiderbuy  mark l perrydirectorbuy  sanofimajor shareholderbuy  data available from  forward headlines headline trends for myokardia nasdaqmyok latest headlines for myokardia nasdaqmyok source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlinemyokardia inc nasdaqmyok insider sells  in stockwwwamericanbankingnewscom  july  at  pmetfs with exposure to myokardia inc  july  financeyahoocom  july  at  ammyokardia inc breached its  day moving average in a bullish manner  myokus  july  financeyahoocom  july  at  ammyokardia inc nasdaqmyok given consensus rating of buy by brokerageswwwamericanbankingnewscom  july  at  pmetfs with exposure to myokardia inc  july  financeyahoocom  july  at  ammyokardia inc – value analysis nasdaqmyok  july  financeyahoocom  july  at  ammyokardia inc breached its  day moving average in a bullish manner  myokus  july  financeyahoocom  july  at  ammyokardia inc nasdaqmyok upgraded at thestreetwwwamericanbankingnewscom  july  at  ammyokardia inc breached its  day moving average in a bearish manner  myokus  june  financeyahoocom  june  at  ammyokardia inc myok given average recommendation of buy by analystswwwamericanbankingnewscom  june  at  pmetfs with exposure to myokardia inc  june  financeyahoocom  june  at  ammyokardia inc myokus earnings analysis q  by the numbers  june  financeyahoocom  june  at  pmmyokardia inc breached its  day moving average in a bullish manner  myokus  june  financeyahoocom  june  at  pmmyokardia inc myok given consensus recommendation of buy by brokerageswwwamericanbankingnewscom  may  at  pmmyokardia inc myok downgraded by thestreet to dwwwamericanbankingnewscom  may  at  pmmyokardia inc myok stock rating lowered by zacks investment researchwwwamericanbankingnewscom  may  at  ammyokardia inc expected to earn q  earnings of  per share myokwwwamericanbankingnewscom  may  at  ammyokardia inc myok earns outperform rating from bmo capital marketswwwamericanbankingnewscom  may  at  pmmyokardia reports q lossfinanceyahoocom  may  at  pmmyokardia inc myok announces earnings results misses estimates by  epswwwamericanbankingnewscom  may  at  pminvestor network myokardia inc to host earnings callfinanceyahoocom  may  at  pmmyokardia reports first quarter  financial results and operational progressfinanceyahoocom  may  at  pmmyokardia myok given coverage optimism score of wwwamericanbankingnewscom  may  at  pmmyokardia inc myok receives  consensus price target from brokerageswwwamericanbankingnewscom  may  at  ammyokardia myok receives daily coverage optimism score of wwwamericanbankingnewscom  may  at  ammyokardia to announce first quarter  financial results and host conference call on tuesday may  financeyahoocom  may  at  pmmyokardia inc myok given average rating of buy by brokerageswwwamericanbankingnewscom  may  at  pmmyokardia myok getting somewhat positive news coverage report findswwwamericanbankingnewscom  april  at  amhow a new biotech model looks to disrupt a fatal genetic diseasewwwbizjournalscom  april  at  pmmyokardia inc – value analysis nasdaqmyok  april  financeyahoocom  april  at  pmmyokardia inc breached its  day moving average in a bullish manner  myokus  april  financeyahoocom  april  at  pmmyokardia myok given daily news impact rating of wwwamericanbankingnewscom  april  at  amshort interest in myokardia inc myok drops by wwwamericanbankingnewscom  april  at  pmmyokardia myok getting somewhat favorable press coverage report findswwwamericanbankingnewscom  april  at  pmmyokardia appoints david meeker md to board of directorsfinanceyahoocom  april  at  ametfs with exposure to myokardia inc  april  financeyahoocom  april  at  pmmyokardia inc breached its  day moving average in a bearish manner  myokus  april  financeyahoocom  april  at  ammyokardia inc myok receives consensus recommendation of buy from analystswwwamericanbankingnewscom  april  at  pminsider selling myokardia inc myok insider sells  shares of stockwwwamericanbankingnewscom  march  at  pmmyokardia inc myok ceo anastasios gianakakos sells  shareswwwamericanbankingnewscom  march  at  pmbriefmyokardia appoints kim popovits wendy yarno to boardwwwreuterscom  march  at  ammyokardia appoints kim popovits and wendy yarno to board of directorsfinanceyahoocom  march  at  ammyokardia inc myok to post q  earnings of  per share wedbush forecastswwwamericanbankingnewscom  march  at  ambriefmyokardia q net income  mlnwwwreuterscom  march  at  pmmyokardia reports fourth quarter and full year  financial results and operational progressusrdyahoocom  march  at  ammyokardia reports q lossusrdyahoocom  march  at  ammyokardia inc files sec form k regulation fd disclosure financial statements and exhibitsbizyahoocom  march  at  am stocks trending with monster volumewwwthestreetcom  march  at  ammyokardia to present at cowen and company th annual health care conferencefinanceyahoocom  february  at  ambriefmyokardia says first subjects dosed in cardiomyopathy drug studywwwreuterscom  february  at  pm social chart myokardia myok chart for friday july   this page was last updated on  by marketbeatcom staff anastasios gianakakos senior vice president of corporate and business development map pharmaceuticals inc  spoke login register add company add person add topic login or home  people  anastasios gianakakos advanced search faq javascript is disabled bio edit anastasios gianakakos tassos gianakakos senior vice president of corporate and business development map pharmaceuticals inc mountain view ca find other people named anastasios gianakakos general info wholesaler of drugs and sundries add tags— eg finance businessbusiness anastasios e gianakakos senior vice president of corporate and business development mr gianakakos brings to map pharmaceuticals more than  years of experience and leadership in business development in the pharmaceutical sector mr gianakakos joined map pharmaceuticals from codexis inc a private company he helped spinoff from maxygen in  while at codexis mr gianakakos held a variety of leadership positions most recently senior vice president business development and head of codexis’ pharmaceuticals business unit mr gianakakos played a key role in raising private financing and helping grow the company’s revenues and establish its operational and commercial infrastructure prior to codexis mr gianakakos was director of business development at maxygen where he led maxygen’s business development and commercial efforts in the pharmaceutical and fine chemical area and supported maxygen’s financing activities before joining maxygen mr gianakakos worked as a process engineer at merck  co providing technical support for merck’s biologics operations mr gianakakos received a bsc in chemical engineering and a bsc in economics from the massachusetts institute of technology a msc in biotechnology from northwestern university and an mba from harvard business school not who youre looking for find other anastasios gianakakos on spoke contact telephone email background report public records powered by digital info wwwmappharmacom na na na na na na resume edit career map pharmaceuticals inc senior vice president of corporate and business development education edit add a degree— eg bachelors in business administration blogs by industry voices there are currently no blogs by industry voices achievements and recognition edit add an achievement andor recognition— eg man of the year forbes  notable links edit the links below are powered by bing search results click edit to customize videos edit add a videofrom youtube or vimeo executives  featured people at map pharmaceuticals inc christopher chai chief financial officer thomas armer chief scientific officer charlene friedman vice president timothy nelson president and chief executive officer stephen shrewsbury vice president clinical and regulatory affairs scott borland senior director of cns programs and technical operations deleon mitts senior staffing consultant jerry okikawa senior director ventures created on jun   by spoke   edited on jun   by spoke   page completion  websiteblog industry career summary add a social network add a video add  achievements add  notable links add education add a photo view more view less share this page add page add company add person add topic copy this code to embed a widget div idspokerootdiv scriptfunctiond s id document script spokewidgetjsscript div classspokewidget datahostwwwspokecom datatypeperson dataidececcab datawidth dataheight datascrollno dataframebordernonediv div stylefontsize pta hrefhttpwwwspokecompeopleanastasiosgianakakosececcabanastasios gianakakosa widget provided by a hrefhttpwwwspokecomspokeadiv public records our partner can help you find public records for anastasios more on some of spokes content providers become a spoke content provider learn more anastasios gianakakos  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in anastasios gianakakos dir president and chief executive officer at myokardia inc view full profile are you anastasios gianakakos claim your profile   sign up for equilar atlas and view anastasios gianakakoss full profile with equilar atlas you can identify corporate executives in anastasios gianakakoss network and community follow changes in anastasios gianakakoss employment and moneyinmotion connect with anastasios gianakakos through your network of contacts anastasios gianakakoss executive work history current dir president and chief executive officer myokardia inc past to view anastasios gianakakoss complete executive work history sign up now education mba harvard university ms northwestern university bs massachusetts institute of technology age      anastasios gianakakoss biography mr gianakakos has served as our chief executive officer and president since october  and has been a member of our board of directors since october  prior to joining us mr gianakakos was senior vice president and chief business officer at map pharmaceuticals inc a biopharmaceutical company from september  to march  when it was acquired by allergan plc prior to map pharmaceuticals mr gianakakos led the formation of codexis inc a spinoff of maxygen inc in  at codexis mr gianakakos served as president and senior vice president business development and global head of codexis pharmaceuticals business unit  read more mr gianakakos has served as our chief executive officer and president since october  and has been a member of our board of directors since october  prior to joining us mr gianakakos was senior vice president and chief business officer at map pharmaceuticals inc a biopharmaceutical company from september  to march  when it was acquired by allergan plc prior to map pharmaceuticals mr gianakakos led the formation of codexis inc a spinoff of maxygen inc in  at codexis mr gianakakos served as president and senior vice president business development and global head of codexis pharmaceuticals business unit before forming codexis mr gianakakos was director of business development at maxygen a biocatalyst development company where he led the companys business development efforts for its vaccine and bioindustrial platforms as well as financing activities including the companys initial public offering prior to maxygen mr gianakakos was a process engineer in merck  co incs vaccine division mr gianakakos holds bsc degrees in chemical engineering and economics from the massachusetts institute of technology an msc in biotechnology from northwestern university and an mba from harvard business school mr gianakakos qualifications to serve on our board of directors include his role as our principal executive officer and more than  years of management experience in the pharmaceutical industry source myokardia inc on    sign up for equilar atlas and view anastasios gianakakoss full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like anastasios gianakakos more specifically youll be able to identify corporate executives in anastasios gianakakoss network and community follow changes in anastasios gianakakoss employment and moneyinmotion connect with anastasios gianakakos through your network of conections view full profile   search for over  executive profiles bio example anastasios gianakakos anastasios gianakakoss connections  sign up now to view anastasios gianakakoss  connections » mary b cranston board member visa inc arnold a pinkston former senior vice president general counsel and secretary beckman coulter kevin p starr board member alnylam pharmaceuticals inc kimberly j popovits chairman of the board president and chief executive officer genomic health inc alan shaw former president and chief executive officer codexis inc mark l perry board member nvidia corporation david e pyott lead independent director avery dennison john g freund board member tetraphase pharmaceuticals inc jonathan c fox former consultant myokardia inc carl s goldfischer board member enteromedics inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   anastasios gianakakos   decypha sign in  welcome guest regions gcc  levant  mena  north africa gcc bahrain  kuwait  oman  qatar  saudi arabia  united arab emirates levant iraq  jordan  lebanon  palestine north africa egypt  libya  morocco  tunisia others iran  turkey  united kingdom  united states advanced search news markets companies research funds fixed income money markets commodities fx economics analysis more sign in membership customize your decypha logout welcome decypha alerts home people profiles people profile anastasios gianakakos profile full name anastasios gianakakos country biography anastasios e gianakakos has served as our senior vice president and chief business officer since july  and previously as our senior vice president designations date designation entity entity description country  map pharmaceuticals inc  united states check all the individuals in check the list request a trial title select mr mrs ms miss dr prof first name last name job title select asset managers corporate banks investment managers wealth managers consultants  advisors legal practioners academics hedge funds private equity analysts traders equity research analysts phone company email country select afganistan albania algeria american samoa andorra angola anguilla antarctica antigua and barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana bouvet island brazil british indian ocean territory brunei bulgaria burkina faso burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island cocos keeling islands colombia comoros congo cook islands costa rica cote divoire ivory coast croatia hrvatska cuba curacao cyprus czech republic czechoslovakia former denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands malvinas faroe islands fiji finland france france metropolitan french guiana french polynesia french southern territories gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guernsey guinea guineabissau guyana haiti heard and mcdonald islands honduras hong kong hungary iceland india indonesia iran iraq ireland isle of man israel italy jamaica japan jersey jordan kazakhstan kenya kiribati kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles neutral zone new caledonia new zealand aotearoa nicaragua niger nigeria niue norfolk island north korea northern mariana islands norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russia rwanda s georgia and s sandwich isls saint kitts and nevis saint lucia saint vincent and the grenadines samoa san marino sao tome and principe saudi arabia senegal serbia seychelles sierra leone singapore slovak republic slovenia solomon islands somalia south africa south korea south sudan spain sri lanka st helena st pierre and miquelon sudan suriname svalbard and jan mayen islands swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu us minor outlying islands ussr former uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city state holy see venezuela vietnam virgin islands british virgin islands us wallis and futuna islands western sahara yemen yugoslavia zaire zambia zimbabwe comments required fields   submit already registered login attempt was not successful please try again username email password enter characters   login forget your password by job title asset managers  corporate banks  investment managers  wealth managers  consultants  advisors  legal practitioners  academics  hedge funds  private equity analysts  traders  equity research analysts by scope equity  fixed income  funds  excel  analytical tools  markets  prices  money market  news  industry  ipos  mergers  acquisitions  commodities  economics covered countries and exchanges add your company   add yourself   terms and conditions   privacy policy   about directfn copyright  directfn all rights reserved data not available login login attempt was not successful please try again username email password enter characters forget your password back to top support  feedback ask for free trial request a trial title mr mrs ms miss dr prof first name last name email phone promo code country select afganistan albania algeria american samoa andorra angola anguilla antarctica antigua and barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana bouvet island brazil british indian ocean territory brunei bulgaria burkina faso burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island cocos keeling islands colombia comoros congo cook islands costa rica cote divoire ivory coast croatia hrvatska cuba curacao cyprus czech republic czechoslovakia former denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands malvinas faroe islands fiji finland france france metropolitan french guiana french polynesia french southern territories gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guernsey guinea guineabissau guyana haiti heard and mcdonald islands honduras hong kong hungary iceland india indonesia iran iraq ireland isle of man israel italy jamaica japan jersey jordan kazakhstan kenya kiribati kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles neutral zone new caledonia new zealand aotearoa nicaragua niger nigeria niue norfolk island north korea northern mariana islands norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russia rwanda s georgia and s sandwich isls saint kitts and nevis saint lucia saint vincent and the grenadines samoa san marino sao tome and principe saudi arabia senegal serbia seychelles sierra leone singapore slovak republic slovenia solomon islands somalia south africa south korea south sudan spain sri lanka st helena st pierre and miquelon sudan suriname svalbard and jan mayen islands swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu us minor outlying islands ussr former uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city state holy see venezuela vietnam virgin islands british virgin islands us wallis and futuna islands western sahara yemen yugoslavia zaire zambia zimbabwe company job title select academics asset managers consultants  advisors corporate banks equity research analysts hedge funds investment managers legal practioners private equity analysts traders wealth managers comments required fields   submit contact us hello please use the below form for product support  feedback name   email  phone number   preferred contact method  email phone technical support x     slhopsdirectfnnet your account manager is   get a decypha membership to view this content get a decypha membership get the membership of decypha premium package to access more exciting features including advanced analytical tools and the pro  package pro  is designed keeping active investors in mind and offers a flexible framework to view information and do analysis the way you desire all you need to access these valuable features is to click on the get a membership button and submit your details to our sales team upgrade your membership account is not entitled to view this information please contact your account manager to upgrade your membership email  supportdecyphacom register to view this content decypha free registration register free with decypha and get access to realtime price information and many other features including technical scanner fundamental screener etc just click the registration button submit your details and get registered for free anastasios gianakakos  map pharmaceuticals insider transactions  tipranks go prologin  sign up follow✓get real time transactionsinsider detailsanastasios gianakakosmap pharmaceuticals mappsvp cor  business dev not rankedanastasios gianakakoss performanceanastasios gianakakos has not reported any informative transactions and therefore cannot be rankedhow are insiders ranked insider holdings  myokardia inc myokmsee the top stocks by insiders  insider rolesmyokardia inc myok president and ceo directorsee the top  corporate insiders  anastasios gianakakoss trading historybased on form  follow✓get real time transactionscompany nameinsider positionholding valuelast transactionlast transaction amountlast transaction datemyokmyokardia incpresident and ceo directoruninformative selljul  mappmap pharmaceuticalssee all insider trading from today you may also likemeet our smart portfolio see what top analysts say about your stocksget a breakdown of the different strategies based on detected insider trading activityfind the best performing analyst in each sector follow them so you never miss a recommendationrelated linkshow can i benefit from insider trading see the top  corporate insiders go to hot stocks by insiders find which stocks insiders traded today become a tipranks memberget the best investing tips  hacks straight to your emailfree membershipsubmitinsider trading daily newsletterprofessional daytrading strategy based on predictive insider transactionsannual return learn more powered by gianakakos anastasios top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active gianakakos anastasios • mountain view ca how do i update this listing gianakakos anastasios is based out of mountain view whalewisdom has at least  insider transactions form  in our database for gianakakos anastasios summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from gianakakos anastasios enter your email address below and choose submit your email cancel contact info gianakakos anastasios  bayshore parkway mountain view ca     business phone  sec sic codepharmaceutical preparations recent sec filings  filed on   filed on   filed on   filed on  a filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free